Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05364125
Other study ID # OlfactoryTrainingHKRCT
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2022
Est. completion date June 30, 2025

Study information

Verified date November 2023
Source Pamela Youde Nethersole Eastern Hospital
Contact Kai Chuen Fergus Wong, FRCSEd(ORL)
Phone 64600771
Email wkc568@ha.org.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

- Causes of olfactory dysfunction can be classified into conductive and sensorineural causes. - Conductive causes are mainly due to structural nasal problem, which can be treated by nasal surgery - Sensorineural causes included post-infection, post-head injury, post Head and Neck irradiation and other central nervous system diseases. - Olfactory Training is well established treatment for sensorineural olfactory dysfunction in foreign countries. - Olfactory Training by neurological chemosensory stimulation using aromatic substances delivered via electronic portable aromatic rehabilitation (EPAR) diffuser was proved to be effective treatment in COVID-19 related olfactory dysfunction in recent Hong Kong study. - However, there is a lack of local study on the effect of Olfactory Training in other non-COVID-19 sensorineural causes of olfactory dysfunction in Hong Kong population.


Description:

Design Prospective double-blinded randomized control trial. Study Period 1/7/2022 - 30/6/2024 for case recruitment. Suitable patient will be recruited. Informed consent will be signed. Objective smell assessment will be done using the University of Pennsylvania Smell Identification Test (UPSIT) and Butanol Threshold Test (BTT). Subjective quality of life score will be obtained by Sino-Nasal Outcome Test (SNOT-22). Subjective smell and taste assessment will be assessed by Visual Analogue Scale (VAS). Patient will be randomized into treatment group and control group using computer generated list by an independent nursing staff. Doctors and the patients will be blinded during the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Olfactory dysfunction > 6 months and < 5 years Exclusion Criteria: - History of significant head injury (fracture, ICH) - History of brain surgery - History of nasal surgery - Active nasal disease - Active neurological disease - Poor premorbid status/ non-communicable patients - Mentally incompetent patients - <18 years' old - Pregnancy - Hypersensitivity to the aromatic substance.

Study Design


Intervention

Other:
Olfactory Training
Four aromatic substances will be used (Citrus limon, Eucalyptus radiata, Pelargonium graveolens, Juniperus virginiana)
Control
Normal Saline will be used

Locations

Country Name City State
Hong Kong Pamela Youde Nethersole Eastern Hospital Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
Pamela Youde Nethersole Eastern Hospital

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Olfactory threshold changes after olfactory training after 3 months Parameter:
Olfactory threshold using Butanol Threshold Test (BTT)
3 months after starting smell training
Primary Olfactory identification score changes after olfactory training after 3 months Parameter:
Olfactory identification using Smell Identification Test (UPSIT)
3 months after starting smell training
Primary Quality of life changes after olfactory training after 3 months Parameter:
Subjective quality of life score using Sino-Nasal Outcome Test (SNOT-22)
3 months after starting smell training
Primary Taste and smell changes after olfactory training after 3 months Parameter:
Subjective smell and taste assessment using Visual Analogue Scale (VAS)
3 months after starting smell training
See also
  Status Clinical Trial Phase
Terminated NCT04964414 - Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19 Phase 1/Phase 2
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Completed NCT05445921 - Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction Phase 1/Phase 2
Withdrawn NCT02179554 - Does Cardiopulmonary Bypass Change Olfaction?
Completed NCT04957563 - Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia N/A
Terminated NCT03680911 - NAC for Head Trauma-induced Anosmia Phase 3
Completed NCT04657809 - Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia Phase 2
Completed NCT04853836 - Olfactory Disfunction and Co-ultraPEALut Phase 4
Recruiting NCT05040659 - Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
Recruiting NCT05562050 - Characteristics of the Anosmic Olfactory Mucosa
Completed NCT05152030 - The Clinical Applicability of the 'TIB' Olfactory Test Device
Recruiting NCT05384561 - Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19 N/A
Enrolling by invitation NCT04764981 - Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19) N/A
Withdrawn NCT04408391 - Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
Completed NCT04361474 - Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity Phase 3
Completed NCT03990766 - Smell Changes & Efficacy of Nasal Theophylline Phase 2
Completed NCT04797936 - BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 Phase 4
Recruiting NCT04528329 - Anosmia and / or Ageusia and Early Corticosteroid Use Phase 4
Completed NCT04789499 - Smell in Covid-19 and Efficacy of Nasal Theophylline Phase 2
Recruiting NCT04384042 - Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study